VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial

Details

Language :

English

ISSN :

09237534

Volume :

32

Issue :

7

Database :

Academic Search Index

Journal :

Annals of Oncology

Publication Type :

Academic Journal

Accession number :

152686456

Full Text :

https://doi.org/10.1016/j.annonc.2021.04.010